• June 16-19, 2025
  • Boston Convention & Exhibition Center

Sessions

Loading

Vyro Bio Inc

Thursday, June 06, 2024
Start-Up Stadium Session
Platform for Therapeutics
5B
Company Description: Vyro is a worldwide pioneer in the development of therapies and drug-delivery viral vectors based on Zika. Its technology is grounded on genetically modified Zika virus for (i) the treatment of CNS tumors, and (ii) viral vector for gene delivery, with solid differentials: Oncolytic therapy: • High efficacy: viral tropism for tumor stem cells present in cancer; • Lower toxicity: selective virus for tumor cells and viral inhibition system in normal cells; and • Lower cost than existing technologies: no need for specialized equipment. Viral vector: • Safety: low pathogenic and no-replicative viral vector with less inflammatory response • Stability: controlled transgene expression in a caping independent process. • Controlled cell tropism with a natural and controlled tropism to the brain and eyes; • Payload: Transgene sequence carrying capability up to 10 kb.

Vyro Bio Inc
Company Website: http://www.vyrobio.com

Company HQ City

SAO PAULO

Company HQ State

SAO PAULO

Company HQ Country

Brazil

CEO/Top Company Official

Dr. Carolini Kaid
Primary Speaker
Carolini Kaid
CEO/CSO
Vyro Bio Inc
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS